论文部分内容阅读
目的观察吡柔比星为主要药物经导管化疗加栓塞联合治疗晚期肝癌的疗效。方法以吡柔比星为主要药物经导管联合化疗加栓塞治疗晚期肝癌142例。结果近期有效率59％，AFP下降率71％，主要副作用为胃肠道反应。结论采用吡柔比星为主的药物联合化疗加栓塞冶疗晚期肝癌疗效满意，毒副作用低。
Objective To observe the efficacy of pirarubicin as the main drug in the treatment of advanced hepatocellular carcinoma by transcatheter arterial chemoembolization combined with embolization. Methods 142 cases of advanced hepatocellular carcinoma were treated with pirarubicin as the main drug through catheter combined with chemotherapy and embolization. The results of the recent 59% efficiency, AFP rate of 71%, the main side effects of gastrointestinal reactions. Conclusion The use of pirarubicin as the main drug in combination with chemotherapy and embolization for the treatment of advanced hepatocellular carcinoma is satisfactory, with low toxicity and side effects.